Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Nightingale, Q4'23

By Inderes9/20/2024, 11:00 AM
Nightingale Health

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Tim
00:00 - 44:05

Good afternoon, and welcome to the webcast for the financial year of Nightingale Health. Today, we will go through the financial year. We look at the key achievements. We go through the numbers. We see the business targets for the next financial year. And then we have the financial calendar and Q&A at the end. My name is Stan, and I'm the CEO and founder of Nightingale Health. Let's start with the first agenda point. I will briefly tell you what Nightingale is all about. So Nightingale Health exists to build sustainable healthcare and reduce health inequalities. So why do we need a more sustainable healthcare system? Because the current healthcare system is not equitable. The healthcare system, if we briefly examine the problem. The healthcare system is overburdened with too many sick people, and it's overburdened with diseases that could have been prevented. Now we talk a lot about healthcare problems. We talk a lot about healthcare costs. And actually, it's the chronic diseases that are the core of the problem. So let's examine this a bit more in detail. So, the core idea of our healthcare system, our primary care system, is to promote health and prevent diseases. And actually, the healthcare system that we have today is constantly promoting health and preventing diseases. But the problem is really that the tools we are using do not scale well. And because of this, prevention doesn't work the way it should. And interestingly, the goal to prevent diseases is featured in many medical guidelines. It's something that everyone agrees on. But the real problem is that we don't have the tools to actually do it. And when we look at this in numbers, 90% of healthcare costs come from chronic diseases. And the silver lining is that four out of five could have been prevented. So I think it's quite clear that change is needed. So what can we do? The answer is actually very simple. The primary care system needs better tools for prevention because with better tools, we can actually reach the benefits of prevention. And as I showed in the previous slide, we are now talking about the biggest problem in healthcare. We fundamentally know what the reason for the problem is. We have too many sick people. We know what the diseases are that are causing the problems, and we know that we can prevent these diseases. The only thing we are really lacking are the tools to improve prevention. And this is exactly what Nightingale Health Plc is all about. This is what we mean when we say that we are building a more sustainable healthcare system. Because when we put prevention into action. That's the roadmap to have fewer sick people. And when we have fewer sick people, we are actually initiating a chain reaction that yields better health outcomes. It's building a better healthcare system. Um. So if you look at this in a bit more detail. So as I said, prevention in the current primary care system is done all the time. But the tools require a lot of resources and they don't scale very well. I think at the very core of the public discussion around health care are the challenges with resources. We don't have enough resources. We don't have enough healthcare professionals to take care of all the sick people. Consequently, it doesn't scale well, because if you have to use a lot of healthcare professionals' time, it doesn't scale effectively. Now, if we bring better tools for prevention, we can do prevention more efficiently. We can offer preventative solutions to a broader group of people, even for entire populations. And then when we detect the risks while people are still healthy. We can help to reduce the risks. And with that, keep the healthy people healthy. So then, this is what we can achieve with this prediction: a reduction in the number of sick people. Then we have the cost savings. Ultimately in healthcare, we can reorganize the way we take care of the sick. And we should do that. Of course, we can implement different information technology solutions and various AI solutions. We can implement various strategies to optimize the current system that is taking care of the sick. But if you really want to change how costs are accumulating, I think the only logical and feasible solution is to have fewer sick people, and that we can achieve with prevention. And then, of course, we need to build this in a sustainable and equal way. So it's not what Nightingale is all about. This is not the technology for the wealthiest 1%. This is a technology for everyone. This is technology that you can take to a population. We call it the Nightingale Health Check. And the Nightingale Health Check is an efficient and effective tool for large-scale prevention. And I will share with you how it works. Because what I've just said, they are kind of big words. We are talking about one of the biggest problems in the world because, eventually, if we have more and more sick people all the time, who will go to work, how do we run the society? So it's not only a healthcare problem that I'm talking about here, it's a broader societal problem that we have to solve. It's not optional. It's something that we really have to solve, and we need to take action quickly. And this is where Nightingale's Health Check can make a significant contribution. So to give a bit of context, let's have a comparison. A couple of comparisons here. I think it's quite important to understand what the Nightingale Health Check is actually doing. What we are actually doing is performing the same risk detection or risk assessment for chronic diseases that is already being done by the current healthcare system. It's the same thing. But what we do, we do it in a much more fundamentally efficient and scalable way, and it's more cost-effective. The results that we provide are not new. It just makes the process much more efficient. And now, if you go back to what I said earlier about prevention, this is the way we can actually scale prevention to an entire population. This is how we are no longer using healthcare professionals' time for risk detection. And with this, we build the core foundation for the preventative healthcare system. So let's compare. Here in the slide, on the left-hand side, we have the current risk assessment tools. And these tools are being used all the time around the world. For cardiovascular disease here in Finland, we have pain risk. The same thing in the United States is ASCVD. We are using SCORE two. In Europe, we are using the Framingham score in multiple countries around the world. This is for cardiovascular disease. For every disease, we have these clinical standard risk tests. So what do they do? Their risk detection capability. They have good performance and require specific inputs. In order to perform the test, you need to collect numerous data points. You need to do lab tests. You need to do questionnaires. You need to do clinical examinations. For example, with cardiovascular disease, you need to measure blood pressure. You measure a BMI. You ask for the body mass index. You ask about family history, and then you conduct the lab work. Evaluating the risk for the disease requires a significant amount of healthcare professionals' time. Then, the current method also involves evaluating one risk at a time. So if you are addressing everyone, I think everyone understands this. So if you go to see your doctor, they evaluate your risk for cardiovascular disease. They don’t evaluate your risk for other conditions. This is a risk for other diseases. One disease risk at a time. Every disease risk being evaluated or assessed requires different data points to collect. And the more risks you evaluate, the more time you spend. So in summary, the current way is inefficient because it's very resource intensive. It takes a lot of time for healthcare professionals. That's why we don't run risk assessments on a population-wide scale. In some countries, this is being implemented. But I mean it's very expensive, and the scalability problem is still there. And the fact is that we would like to run this for everyone, because the better we detect the risks, the better we can take early actions. So let's compare this to the Nightingale solution. So, the risk detection capability and performance of our test are either equal to or superior to others. So we match. And as I said, it's the same thing if you run ASCVD. If you run thin risk. To assess the cardiovascular disease risk. You can also run Nightingale. It's the same risk detection. You are doing the same risk assessment. Now, the difference is why it scales in a completely different way than the current risk assessment tools. We need just a single blood sample and eight and six as clinical parameters. Nothing else, nothing else. So, it's a fundamental change in how the risk can be assessed. And then, there is more. So, the current way of doing things assesses only one disease risk at a time. It has many challenges because, what do you want to do? You want to create a holistic picture of the disease risks that people may have. So now, the Nightingale test. It detects multiple disease risks every time. Automatically. Still, one blood sample, eight and six clinical parameters. So, I mean, the difference now, if we make it a bit more concrete, is significant. Assessing the risk with current risk assessment tools takes 15 to 30 minutes per disease. With Nightingale, because you don't need to collect any clinical data. It's basically just a couple of minutes. You just need to draw the blood sample and then you are good to go. So, it requires way fewer resources from healthcare professionals. And importantly, with the Nightingale approach, the time of healthcare professionals can be targeted to people who actually need help from healthcare professionals, because when we know the risks, we can also target the healthcare services to those in need. And this is when you look at this in the bigger picture. This is extremely important. I think we actually have sufficient resources in healthcare. The problem is that resources are not targeted optimally, but to effectively target these resources, one must first understand how to do so. And that's basically what the primary care aspect boils down to—knowing the risk. And now we can do this on a large scale, even for entire populations. So what happens here is that the Nightingale Health Check replaces the current risk assessment tools. And now, this is not just a vision like, 'Oh, we're going to do this in ten years.' And then amazing things happen. It's already in nationwide use in healthcare, in primary care. So it's already happening. The results are very strong. I want to show another slide about the same thing because I think this is the key. This is the core aspect of Nightingale Health's technology. This is the core aspect of how we are helping to build a better healthcare system worldwide. This is all about the competitive advantage of this technology. This is something that, to my knowledge, no other company in the world can do at a similar level. So let's compare again. Using the use case, take the risk assessment in Finland. So in Finland, we have this technology in nationwide use in the primary care system as part of the occupational health care in Finland. Occupational health care is part of the primary care system. So, let's discuss the current risk assessment tools first. The same thing as in the previous slide. But now I go into more detail. So, the current clinical methods to assess risks for chronic diseases. In Finland, we have Finrisk, which is for cardiovascular disease. We have FindeRisk, which is for type two diabetes. We have tests for kidney disease, liver disease, and lung diseases. Um, how are these tests being conducted? Now, this is the clinical standard. This is from the guidelines. So here you can see every disease. So with FINRISK and FINDRISC, you need to collect all of these data points that are being shown in there. So now, if you imagine the time it takes to collect those data points within the risk assessment for type two diabetes, you need to collect all of these data points shown in the slide. For chronic kidney disease, you collect the data points shown in the slide. Now imagine that you do all of these tests. You test for the risks associated with CVD, type 2 diabetes, chronic kidney disease, liver disease, alcoholic liver disease, lung cancer, and COPD. So, nobody does it. Nobody does it. I mean, come on, the time needed to do this is, uh, unbearable. You really don't do this. I'm now discussing the national use of primary care. You may be able to go to a private clinic and buy this if you have the money. But that's the kind of scalable primary care tool. This is not doable with the current risk assessment tools. However, this is something that should be done. And I think there is a very good alignment that detecting the risks early on should be done. So now let's take Nightingale. One blood sample detects multiple disease risks simultaneously. The required clinical data to run all of these disease tests. Blood samples test for multiple disease risks simultaneously using the Nightingale Health Check. With equal or better performance. And of course, I may be a bit biased when I say this, but it is truly groundbreaking. This changes the way health risks can be detected. And this is the core for the future of primary care in every health system in the world. I think it's quite exciting. And it's available today. We can scale this to national use. We are building capabilities in multiple locations around the world. And now we are scaling this to be adopted in different healthcare systems. And here is just an example of how this happens in reality. There is a picture of the risk assessment reports. You can look at this in more detail on our webpage. Additionally, healthcare professionals frequently request the LDL cholesterol levels beyond just the overall risks. I want to see HDL cholesterol, and I want to look at the different biomarkers that are used to run diagnostics in healthcare. Now we also deliver this. So, you don’t need to run your clinical chemistry. We also deliver biomarkers aligned with the gold standard. So again, you use the Nightingale. They are not akin to Nightingale biomarkers. They are the same biomarkers that are being used in medicine all the time. So, in addition to the risk detection capability, you also get the biomarkers. This is why this tool can be adopted for healthcare use immediately. It doesn't take anything away. It provides the same benefits that are being utilized by healthcare providers worldwide continuously. But then it brings a layer with the risk detection that is way more efficient than anything else. Anything else in clinical use. We can also do this. Of course, the majority of the businesses use venous samples because that's the standard in healthcare. But I think there are quite exciting applications with self-collected samples. A person can give the sample themselves from a finger prick. I believe that when we look at healthcare within the next five years, self-collected samples will become more and more of a standard. It's just that we can create a more distributed health system and create more efficiencies. And, it's also nicer for people. You don't have to go anywhere. You just provide the sample at home and then receive the results. And then when you meet with your GP or the clinician, you already have the risk report on the table. It's just better for everyone. All right, so that was the recap of Nightingale and the core value. We are delivering; now let's review the business targets that we had for the previous fiscal year. Uh, so we had three targets: target number one, to win an international commercial contract with a healthcare industry partner; target number two, to win a white label deal. Here, we are referring to the B2C business that we operate, which is based on self-collected samples, and then target number three is regarding our research efforts, with many scientists around the world using Nightingale's technology for medical science. So then we had there a contract value target. Just as a brief summary, we reached all of the targets. I think especially with the first target, the adoption of Nightingale's technology, we made several important announcements and significant deals in the United States. The adoption of Nightingale's technologies is advancing very strongly. I will talk more about this. I will go into more detail in that area. We also had a target regarding FDA approval in the United States. There is a significant change in the FDA ruling. So, in the rules, what are the requirements in the United States? We will be talking about that in more detail soon. But I think the changes that have now taken place in the new ruling put us in a position where the international standards we already have approvals for are applicable. I think they are very applicable for the new FDA ruling. So I think we are in a very good position now to pursue the approvals also in the United States. And then the new ruling also greatly affects the previous model, which required considerable interpretation in understanding the rules. The new ruling clarifies the rules significantly. And we believe it's a very good thing. But I will come back to that. We will come back to that later. Alright, let's go into the key achievements of the past fiscal year. Here we have our international locations. I think what I'm very proud of is that Nightingale, as a company, has around 90 employees. And, we run this business in five different geographical regions. We have very strong results from all of the regions. We have very strong results. Of course, this is like the company journey is still in the early stages. It's in the early stages. In many ways, it is. This takes time, and that should be no surprise. It takes time. But I think now if you look at all of the five locations and see the progress that we are making, it's pretty unbelievable that a team of 90 people can accomplish this. So I think the Nightingale team is one of the most efficient teams in the world. If you look at the results, if you look at the team size, I think it's quite unbelievable. So huge thanks to the Nightingale team once again for reaching all of these achievements. So in Finland, we have the partnership with Terveystalo. Uh, this is where we have the technology in nationwide use, 30% of the Finnish workforce in the country is being tested with this technology, and it is in occupational health. But importantly, in Finland, occupational healthcare is part of the primary care system. In Japan, we made progress by acquiring a company that puts us commercially in a new position. I think we are now in Japan in a very good position to pursue growth in Singapore. We made a partnership with Innoquest Diagnostics. It's part of Pathology Asia, which is the largest diagnostic provider in Southeast Asia, covering a population of 500 million people. Uh, so I think that's also very strong progress in the UK. We have started the new laboratory there. We completed the analysis of the UK Biobank with Nightingale's technology, the largest health data repository in the world. This is because the scale is so immense. When we do data analysis with Nightingale's technology, operating on such a massive scale yields significant results. It's unprecedented. So that gives a lot of confidence then when we also do the healthcare implementation. Um, and then we had some progress with the self-collected samples in the UK. In the US, a lot of new deals were announced. So we had partnerships and deals with major healthcare organizations. So we are working with Mass General Brigham, Weill Cornell Medicine, Kaiser Permanente, Boston Heart Diagnostics, and 23andMe. And, if you look this up, they are some of the most important healthcare customers in the world, not only in the United States. I think many of these organizations are also leading the way in medicine and healthcare. So we are very proud that they want to partner with us. They want to adopt Nightingale's technology. I think it demonstrates that what we have is something that is hugely important in answering the question: how do we build future healthcare systems? So I will go into more detail about all of this. And, we also have this top part of the slide. We have this progress bar, with the progress bar, we want to indicate what the status is. Like, where are we in the journey? As I said earlier, the Nightingale journey, this kind of company takes easily ten years to build the validation, develop the technology, and get everything running. And then you start, step by step, going into the adoption of the technology in healthcare cases. It takes time. So that's why we wanted to give a bit of understanding about how we see the progress in different markets. So in Finland, I think this is the most advanced use case of Nightingale's technology. We are engaged in large-scale healthcare. The nice thing about this collaboration is that here we directly replaced the old way of doing risk assessment. So we directly replaced that with Nightingale's solution. Nightingale solution. And that, of course, brings quite significant sample numbers right away, because these workflows and processes are already taking place. And now, when you switch to Nightingale technology, there are quite a lot of samples involved, but I think it's a very strong achievement. And this is a very important reference. Also, when we look at our business in other countries, after a very long time spent building this technology and developing the company, it’s great to see that there are hundreds of healthcare professionals using this technology on a daily basis. I think it's something; it's a major achievement. Then in Japan, we are in the implementation phase. We acquired Wellness Inc to strengthen our business position. Now, this acquisition enables us to work with the partnerships, provide the technology more broadly to different use cases in Japan, and it's already available in more than 200 hospitals. So now, the next step to advance into large-scale healthcare use is, of course, positioning the technology for use cases where it can scale quickly. But I think this collaboration in Finland is a great reference also to Japan because in the Japanese system, occupational healthcare plays a significant role in how the entire healthcare system has been built. In Singapore, as I mentioned, we made the deal with Innoquest Diagnostics, which is the leading clinical diagnostic service provider. So the reason why we built a partnership like this is that it helps us to get our technology where the samples are already being shipped. So you know, in this kind of business, collecting the samples and managing the logistics is quite a big thing to solve. In Finland, we have solved it ourselves. But now, in international locations, we prefer the models that have very well-built Nightingale capabilities, like a lab within a lab. And now we are building the laboratory. The ramp-up is proceeding as planned and commercially. We estimate the launch will happen in the last calendar quarter of this year. So, we are making good progress. Um, and then, regulatory-wise, I think the Health Sciences Authority in Singapore. We just announced the third approval in this. Well, I think it's pretty much aligned with our results from other regions. But I think it further demonstrates that Nightingale's technology is aligned with the gold standard in clinical medicine and can be used extensively in healthcare. I think it's a very important step also to get these approvals, and now we are very well positioned in Singapore. In the UK. The laboratory is there; we have staffed it. The samples are already being analyzed. And now, I think what we are looking to do next there. Now, we have the local capability in the UK. Now, there are a lot of commercial actions that we can undertake there. The UK Biobank analysis was also very important. Uh, milestone for us. And if you look at the publications done with Nightingale's technology, I think the number of published scientific papers is going through the roof because many research scientists can access the data from the UK Biobank, and they can also realize the benefits of Nightingale's technology in the medical science they are conducting. And with this, we are actually step by step helping to build better tools in healthcare use. In the United States. Um, five extremely important deals. Perhaps I should mention a bit about the nature of the deals. So with 23andMe, we are of course, they are one of the biggest, or perhaps the biggest company in the consumer health area in genetics, and Nightingale’s technology is a great addition to the genetic data. So with genetic data, you can examine what you have inherited, things that you essentially cannot change. And then with Nightingale, you gain an understanding of how your lifestyle affects your body and how your body reacts to your lifestyle. And then when you combine these data modalities, you achieve an even better risk assessment. Of course, with chronic diseases, the lifestyle side has a significant role in impacting the risks. Has the most important role in impacting the risks. Then another example like Mass General Brigham and Kaiser Permanente, they are huge health systems in the United States. Some of the biggest. They are also, I would say, global references in many ways, so working with them, I think it's a great step forward to advance the adoption of Nightingale's technology in the United States. All of these deals will take time to bring these projects into production. But we are making great progress with them. A pilot is running with Boston Heart Diagnostics, for example. So we are also moving in that direction. But we need to take it step by step. I think the important point is to look at the customers and understand how they are operating and what their role is in the healthcare system in the United States. And then we are building the laboratory in the United States. I think that's a very important step with these new customers to be able to serve them locally as well. Um, and then finally, we announced that we acquired all the intellectual property assets of the Velvet Plot collection device. Earlier, we held a license to use and manufacture the device. But, as I mentioned before, looking ahead five years, I believe these self-collected samples will become increasingly vital in enhancing the efficiency of the healthcare system. So far, this blood collection device has been the only one that yields very good results. So in other words, it has very good sample stability over a long time period. So, the sample can be kept queued for up to three weeks after collection. So this helps with the logistics. And then we also wanted to acquire the technology because now we can integrate it better. Also do the analysis. And we are the only company in this field that has the collection device and the analysis capability. So you can get from Nightingale. You get all the components from a single company. I think that will be a strong competitive advantage when we look forward. All right. So that's progress. I think we have achieved quite a lot of things. I could have used even more time to go through all of them, but I think it just describes the great progress that we have managed to achieve over the past fiscal year. And I think we are in an excellent position to continue the rapid progress with these cases. We have already announced, and also with the new deals that are proving promising in our pipeline. So now let's go to the numbers. And I would like to ask our capable CFO to join me on stage. And, let's have the numbers review.

Unknown 1
44:05 - 49:00

Yes, thank you, Tim. Great to be here. Presenting the numbers from our last financial year. So, let's actually start with the cost side of things, because I think it is quite amazing that we have managed to achieve all the great things Tim was talking about. Whilst actually maintaining the same cost level as we've had for the last couple of years. So, it of course means that we are running a tight ship. We are really doing things in a focused manner, in a really efficient way, and also in an effective way, really making things happen. So, the change in our liquid funds, meaning cash and certain short-term investments we are doing for liquidity management purposes. The change in our liquid funds, meaning cash and certain short-term investments we are doing for liquidity management purposes, was at -14.6 million in the previous financial year, which is actually almost the same as in the earlier financial year. Which means that, at the end of the financial year, we had around 66 million in liquid funds available, giving us a really strong financial position to continue executing our strategy and growing our business globally. This provides us with multiple years of runway, definitely enough for us to significantly scale the business globally. Then on the revenue, the revenue for the second half of last financial year was in the same €2 million bracket as it has been for the last couple of half-year periods, landing at €2.6 million, which is at the same time also the highest half-year revenue. Uh, revenue for half a year period ever. It's good to know that the largest part of the revenue still comes from the research business, which is rather volatile in nature. So, you should expect to see some volatility in revenue going forward. But at the same time, we are building this other revenue bucket, if you will, a foundation from the healthcare revenue side, which is then more stable in nature. And now, for instance, we are seeing the first revenue coming into that bucket from this Dataverse occupational health deal that commenced in early H2. And many of the deals Tim was describing have a chance to actually start contributing to that more stable healthcare revenue bucket. And that is, of course, something we really want to grow going forward. Then, just to summarize the numbers for the financial year. So the revenue for the full year landed at 4.358 million, which is a slight 4% increase year over year. But also, at the same time, it is the best full year revenue-wise to date. We also managed to improve our profitability slightly, with EBITDA landing at -10.4 million and our net income at -17.46 million. We are practically debtless. You know that in our balance sheet, our net debt to equity ratio is -76%, which is fantastic. And we have a solid financial position with net cash at €63 million. The difference now between the liquid funds I described two slides ago and net cash is that net cash actually represents liquid funds from which we deduct the interest-bearing debt and leasing liabilities. So I think to summarize our financial position in three points. First of all, it's a really solid and strong position to continue executing our strategy. Uh, and multiple years of runway remaining. Secondly, virtually we have no debt on our balance sheet, which gives us possibilities in the future to leverage our balance sheet if needed for certain projects to scale up the business. And we are also on the path to improve our profitability, where both the increased top line and efficiencies across the board are contributing. So, we are on a good path towards our mid-term target of becoming EBITDA positive in the future. I think that's a short summary of the numbers. Then, back to you, Tom.

Tim
49:00 - 54:49

Thank you. So, looking at the numbers and the progress, I believe the Nightingale journey is moving forward as planned. We are managing the financial position and the financial aspects. The way we've been planning to manage it. We have a solid runway. We very strongly believe that it is enough to reach a positive outcome. Positive. EBITDA. We are winning deals that are very significant. In promoting the adoption of the technology for healthcare use. In our plan, we know it takes time. But I think the speed of the progress is very strong. So we are quite comfortable about the position where we are. And, I think it's a great situation to accelerate forward and reach towards the international ambitions that we have for this company. With that, let's move on to the business targets for the ongoing financial year. We continue with the primary focus. We aim to win new large international deals, particularly in healthcare, targeting these flagship quality deals. The journey, the Nightingale journey, is still in the phase where we need to, uh, we need to win the flagship deals. We need to win new deals because it's the new deals that are driving adoption forward. I actually believe that once we get Nightingale's technology implemented in a few more large-scale healthcare use cases, there is a strong possibility that this technology becomes transformative. It gives such a competitive advantage that if you are without it, how can you compete in risk assessment, which puts us in a rather nice position. That's why we try to win large deals. That's why this is the primary focus of what we are trying to do. We believe this. We can build this into a significant player in international healthcare and go there to target one. That's where we want to deliver. And that's why it's our primary target. Target number two: we are now also bringing more of the numerical side to the table. It's still not the core priority. As I said, the core priority is to win new deals. Driving these deals is propelling the company forward in the best possible way. But also, increasing revenue is our target. So we also want to do deals that help us to bring the revenue up, as cover some of the deals that we have announced can also help to build up the revenue. And then, when we move forward. The more we win the deals, the more we will also give priority to the revenue side of things. But this is a journey. It takes some time, and we are evaluating constantly where our core focus should be. And then target number three: improve efficiency. Efficiency. So, we continue maintaining strong cost control and aim to improve the EBITDA. Same story with the EBITDA. So, as we move forward, we will give more focus and priority to this. But now, it's still time to win the deals. This approach propels the story forward in the most effective manner. Um, and then there are no changes to mid-term business targets, long-term business targets. In the mid-term, we aim to achieve positive EBITDA. And as I said, the runway that we have, we strongly believe that we have a solid roadmap towards that. And then in the longer term, what we aim to do here, is to build an international-scale healthcare technology company. Here you can see the financial calendar and the date for the annual general meeting. And then we move to the Q&A session, and I would like to ask members of our management team to join us on stage. And, let's have a look at the questions.

Timo
54:49 - 54:56

Yes, thank you. Timo, you all talk so much that we only have about five minutes for questions.

Tim
54:56 - 55:01

I'm sorry. It's not because of that. It's because we have so many things that we need to tell.

Timo
55:01 - 55:55

Okay. Agreed. So, a lot of questions. Obviously, for obvious reasons related to our ongoing projects around the world, especially here in Finland, a lot of these things have been discussed during the presentation, but maybe some highlights and clarifications. So let's start with, according to public information as well as our internal resources, the collaboration has started. Well, how significant is the role of trust in sharing information about the revenue coming from the project? But what really is it? I mean, there is a significant role in integrating strategy and also generating revenue. Can you clarify that one more time?

Tim
55:55 - 57:11

Yeah. So you mentioned two words: revenue and reference. And now the priority here is the reference. So this is, of course, when moving the Nightingale story forward; we need to win cases where the adoption of the technology goes to large scale. And for us, working together with Stella has been a great opportunity on one hand to get the technology to be used in large-scale healthcare. But then, on the other hand, there's a lot of collaboration and development together with them. And it's been something where a lot of learning has been exchanged in that partnership. And of course, there is the revenue component. But now we play the long game here. And in the long game, the meaning of this partnership is to have the reference to have the possibility to build something great together with a great customer who is really forward-thinking about how we build a better healthcare system in the future?

Timo
57:12 - 57:30

Okay. Let's continue on that strategic angle then. So internationally, how do you believe that the type of Health Check or this use case can be adapted to other markets and geographical areas that we've been discussing today?

Tim
57:30 - 59:55

Yes, well, I think a short answer is very well, but maybe to give you a bit of an idea beyond a single case. So with Nightingale, we have basically three kinds of use cases. So we have the first one, which is where we detect early risk through early risk detection screening. It's all about how we can detect risks as early as possible. This is part of the preventative healthcare system. This is part of the health insurance system. So there are a lot of use cases for this. So that's the first one. The second usage is that this technology can actually be utilized. We have not announced significant deals around this, but this technology can also be used to help treat people who already have a disease. So this is more of a specialized healthcare application. I think there are good use cases in that segment as well. And then we have the third segment, which is using Nightingale's technology as a KPI. So now we talk a lot. If you search for value-based healthcare on Google, this is what is happening in the United States. There is a strong movement towards paying and focusing on healthcare outcomes. So what is the performance of the activities that healthcare is conducting. So how they are creating value. But there is one problem that is quite a big problem. How do you measure progress if you do something, and how do you know if those actions have been impactful? Actually, Nightingale's technology can be used as a KPI because, honestly, what would be a better KPI for healthcare progress than the change in risk? So if you do something that reduces the risk, you are doing better; essentially, you are enhancing healthcare. So I think this qualifies as a type of KPI. Use cases are also emerging; not that we have deals in that area right now, but I think it's good to think about the technology like this. So risk screening, then helping to take care of the sick, and then the KPI use cases.

Timo
59:56 - 60:07

Okay, thank you. Then, a very frequently asked question is about the probability of getting the product commercially available in Singapore by the end of this year. Yes, no.

Tim
60:08 - 60:11

Yes, it will be available commercially by the end of this year.

Timo
60:11 - 60:20

Okay. Let's see about that. I think we are pretty much out of time.

Tim
60:20 - 60:21

Okay. Let's have a couple more.

Timo
60:21 - 60:49

Okay. Let's have a couple more. So, this also might have captured a good share of something related to that. So, there are these focus areas in different markets, and there is no question regarding how many more laboratories and employees you need to grow substantially worldwide, let's say, in the short to mid-term. And how do you then see the burn rate developing? Related to this?

Unknown 1
60:50 - 60:54

But if we start from the number of laboratories we need. Yes, yes. Mhm.

Tim
60:54 - 62:34

Um, so now when you saw in the presentation, you noticed that we have five locations where we are implementing or have implemented Nightingale technology. That is kind of the core. Uh, because if you look at those markets, there is a lot we can do with these laboratories. Of course, if there is a customer case in some other region where the deal size is just big enough, we go there and implement the laboratory. We can do it. We have quite a lot of experience with this, but maybe to state it as a more general strategy. So we have believed from the very beginning that there's a lot of power in small teams; thus, we are now not like 90 people. What we try to do is ensure that the point is not just to hire another 100 people. That also creates a lot of inefficiencies. Now, with the team size that we have, we can be super efficient. And how do we manage that? We also make progress. One word: focus, focus, focus, focus. So we don't go to the United States and say, 'Oh, call the top 100 customers.' You just create a mess. Juice out of these top 100 customers, the ten most important and viable cases win those, and then you can also manage the costs.

Unknown 1
62:34 - 63:14

Side, and maybe then, fully agree with what you said and then comment on the actual cost side. So naturally, we need some CapEx and OpEx investments when we set up new laboratories. But of course, we undertake these only when we have solid business cases in the pipeline and the revenue from those cases should then offset the increased costs. By far, this means that we should continue to be able to improve our EBITDA and achieve positive EBITDA. Of course, there will be some time like that, but it's not going to be too long. But our solid financial position and the fact that we are debt-free give us the possibility to scale up.

Tim
63:14 - 63:49

And even if we need to invest in this, should a commercial deal arise requiring CapEx investment, we have the debit card, which we have not used at all. Exactly. So I think there's a lot of flexibility in how we build up the growth. And I would say about the number of employees, the day will come when we need to hire a lot more people if we are successful, but then that's when we build the company. There are a lot of changes that we then need to make. Then we do the changes when the time comes, but the time is not now.

Timo
63:50 - 64:21

Okay, so then maybe something that has raised a lot of questions. I mean, this regulatory field has raised a lot of questions in the US, but also elsewhere. Can you somehow summarize how the regulated projects have performed? What was your experience with the regulatory project now expanding into other markets? What is the basis for those? What are the expectations for new markets when rolling out to new geographical areas and all that?

Tim
64:21 - 65:38

So, to briefly summarize the situation. In markets where the rulebook is very clear, it specifies exactly how things need to be done. And there is not a lot of room for interpretation. Typically, the process isn't something that takes years to build up. We have been very successful. I think the recent achievements in Singapore demonstrate very well. I mean, the requirement level in Singapore is very strict. It's very strict. So, when the rulebook is clear, we have made very good progress with the regulatory approvals. And I think now in the United States with the new FDA ruling, that's why we think it's a very good change in the ruling, because it makes the rules clearer than before. We have certain elements in our current quality management system that are compatible out of the box with this new ruling, but this can become very detailed very quickly. We will provide more details about this soon.

Timo
65:40 - 66:09

Okay, perhaps it's time to wrap up the whole presentation and this question-and-answer session. So the last one, priorities. How do Nightingale's priorities look for this ongoing fiscal year, and what can be expected to follow from our press releases and company announcements over the next nine months?

Unknown 2
66:09 - 66:09

Um.

Tim
66:09 - 66:57

So look at the deals. We do look at the progress we make in the deals that are now in the pilot phases. That's it. That describes how we are moving forward. And of course, we place a lot of priority and focus on taking good care of the numbers. That's what we always have. We have been doing it. Of course, it kind of takes investments and it takes time to build these kinds of things up. There is no shortcut in this kind of business. And with these technologies. But I think if you really want to follow the story and see where we are going, look at the deals and the progress we are making in those deals.

Timo
66:59 - 67:07

Okay. Thank you. I think that was pretty much capturing the questions. And we are all set.

Tim
67:07 - 67:23

So thank you everyone for the questions. Um, and, that's it. We will meet again. Have a nice day.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…